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Abstract
Large-scale registries have demonstrated that in-hospital mortality after percutaneous coro-
nary intervention (PCI) varies widely across institutions. However, whether this variation is
related to major procedural complications (e.g., bleeding) is unclear. In this study, institu-
tional variation in in-hospital mortality and its association with PCI-related bleeding compli-
cations were investigated. We analyzed 388,866 procedures at 718 hospitals performed
from 2017 to 2018, using data from a nationwide PCI registry in Japan. Hospitals were strati-
fied into quintiles according to risk-adjusted in-hospital mortality (very low, low, medium,
high, and very high). Incidence of bleeding complications, defined as procedure-related
bleeding events that required a blood transfusion, and in-hospital mortality in patients who
developed bleeding complications were calculated for each quintile. Overall, 4,048 (1.04%)
in-hospital deaths and 1,535 (0.39%) bleeding complications occurred. Among patients with
bleeding complications, 270 (17.6%) died during hospitalization. In-hospital mortality ranged
from 0.22% to 2.46% in very low to very high mortality hospitals. The rate of bleeding compli-
cations varied modestly from 0.27% to 0.57% (odds ratio, 1.95; 95% confidence interval,
1.58–2.39). However, mortality after bleeding complications markedly increased by quintile
and was 6-fold higher in very high mortality hospitals than very low mortality hospitals
(29.0% vs. 4.8%; odds ratio, 12.2; 95% confidence interval, 6.90–21.7). In conclusion, insti-
tutional variation in in-hospital mortality after PCI was associated with procedure-related
bleeding complications, and this variation was largely driven by differences in mortality after
bleeding complications rather than difference in their incidence. These findings underscore
the importance of efforts toward reducing not only bleeding complications but also, even
more importantly, subsequent mortality once they have occurred.
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Introduction
Despite advances in percutaneous coronary intervention (PCI) over the last 40 years, bleeding
has been regarded as one of the most serious procedure-related complications [1, 2]. Once
bleeding complications occur, in-hospital mortality increases by approximately 12% [2]. The
introduction of radial access has contributed to reductions in bleeding complications [3–5];
however, not only access site but also non-access site bleeding complications was indepen-
dently associated with an increased risk of postprocedural mortality [6, 7]. Moreover, the
recent advent of novel potent antithrombotic agents has increased bleeding events in exchange
for a reduction in ischemic events [8, 9]. Especially recently, some populations receiving PCI
comprise patients with a high risk of bleeding [10, 11]; therefore, PCI-related bleeding compli-
cations and their related mortality remain significant issues worldwide.
Large-scale registries have demonstrated that in-hospital mortality in patients underwent
PCI varies widely across institutions [12–14], though the underlying reasons are not fully
understood. We hypothesized that this variation may be involved in bleeding complications
because their incidence or subsequent clinical outcomes can be largely dictated by hospital’s
capacity (e.g., the ability to prevent, expeditiously recognize or properly manage complica-
tions). In this study, therefore, we aimed to investigate the association between institutional
variation in in-hospital mortality and bleeding complications within a representative nation-
wide PCI registry in Japan. Identifying this association has the potential to improve the prog-
nosis of PCI in the contemporary era when patients with a high risk of bleeding are commonly
treated.
Material and methods
Data source and study patients
The Japanese Percutaneous Coronary Intervention (J-PCI) registry is an ongoing nationwide
PCI registry endorsed by the Japanese Association of Cardiovascular Intervention and Thera-
peutics (CVIT) that was designed to record clinical characteristics and in-hospital outcomes of
patients undergoing PCI [15, 16]. In January 2013, the J-PCI registry was incorporated into
the National Clinical Data system, a nationwide prospective Internet-based registry linked to
board certification. Since all hospitals must participate in the J-PCI registry for board certifica-
tion application and renewal, the degree of data completeness is high. Each hospital has a data
manager who is responsible for collecting and recording PCI data. The CVIT holds an annual
meeting of data managers to secure appropriate data collection and performs random audits
(20 institutions annually) to check the quality of abstracted data. The definitions of variables in
the J-PCI registries are available online from the CVIT. This study was conducted in accor-
dance with the principles of the Declaration of Helsinki and approved by the Institutional
Review Board of the Network for Promotion of Clinical Studies (a specialized nonprofit orga-
nization affiliated with Osaka University Graduate School of Medicine in Osaka, Japan). The
requirement for written informed consent was waived because of the retrospective study
design. In accordance with the Transparency and Openness Promotion Guidelines, the data
that support the findings of this study are available from the corresponding author upon rea-
sonable request.
This study population consisted of consecutive cases registered from January 2017 to
December 2018 in the J-PCI registry. Then, cases with missing information in background
characteristics were excluded. Also, we restricted the dataset to institutions that reported at
least one in-hospital death during the study period (Fig 1).
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Definition of variables
Bleeding complication was defined as a PCI-related bleeding event that required a blood trans-
fusion during the index PCI hospitalization. In-hospital mortality was defined as death from
any cause. Other study variables, including patient characteristics, clinical presentation, angio-
graphic and procedural details, and in-hospital outcomes were defined as previously reported
[15].
Model of risk adjusted in-hospital mortality
To account for differences in patient variables that affect mortality, hospitals were stratified
into quintiles according to risk-adjusted in-hospital mortality, which was calculated as follows:
(i) with reference to previous study [17], a multivariable logistic regression model was created
to predict individual patient probability of death using age, sex, smoking within 1 year, hyper-
tension, dyslipidemia, chronic kidney disease, maintenance dialysis, peripheral vascular dis-
ease, previous PCI, previous coronary artery bypass graft surgery, previous heart failure,
cardiogenic shock within 24 hours, clinical presentation (ST-segment elevation myocardial
infarction, non-ST-segment elevation myocardial infarction, unstable angina, or others),
access site, number of diseased vessels, antiplatelet agents given at the time of PCI, and antico-
agulant agents given at the time of PCI as explanatory variables (C-statistic of 0.91); (ii) crude
mortality at each hospital was calculated and predicted probability of death for each patient at
each hospital was averaged to obtain expected mortality; (iii) finally, risk-adjusted mortality at
each hospital was calculated by dividing crude mortality by expected mortality and multiplying
it by overall database mortality. We then ranked the hospitals according to risk-adjusted mor-
tality and stratified them into quintiles (very low, low, medium, high, and very high mortality).
Main analysis and subanalysis
As a main analysis, we calculated incidence of bleeding complications and mortality in patients
who developed bleeding complications for each quintile. As a subanalysis, access and non-
access site bleeding events were assessed individually. In addition, access site bleeding events
were assessed separately for transfemoral access (TFA) and transradial access (TRA). The
Fig 1. Flowchart of study enrollment. PCI indicates percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0261371.g001
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incidence of TFA- and TRA-related bleeding events was calculated among only patients
treated via TFA and TRA, respectively.
Statistical analysis
Categorical data are reported as numbers with percentage and were compared using the chi-
square test. Continuous data with normal distribution are expressed as means with standard
deviation. Continuous data with non-normal distribution are expressed as medians with inter-
quartile range. One-way analysis of variance and the Kruskal–Wallis test were used to compare
continuous data. Incidence of bleeding complications and mortality in patients who developed
bleeding complications are presented as numbers with percentage. Odds ratios (ORs) with
95% confidence interval (CI) were calculated in each quintile relative to very low mortality
hospitals using mixed model logistic regression. Institutions were included in the models as
random intercepts. The Cochran–Armitage test was used to assess trends in complication inci-
dence and mortality after complications among the quintiles. Two-sided P<0.05 was consid-
ered significant. All statistical analyses were performed using R software version 3.6.3 (R
Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 388,866 cases at 718 hospitals were included for analysis. Overall, 4,048 (1.04%) in-
hospital deaths occurred. Patient characteristics according to risk-adjusted mortality quintiles
are summarized in Table 1. In-hospital mortality ranged from 0.22% to 2.46% in very low to
very high mortality hospitals. Compared to other quintiles, the very low mortality quintile of
hospitals had a 1.5-fold higher proportion of hospitals that performed >500 PCI cases per year
(Table 2). TFA was used more frequently in the lower mortality hospitals, whereas TRA was
used more frequently in the higher mortality hospitals. The prevalence of acute clinical presen-
tation, including ST-segment elevation myocardial infarction and non-ST-segment elevation
myocardial infarction, was highest in medium mortality hospitals. Complex PCI cases requir-
ing rotational atherectomy or directional coronary atherectomy were performed predomi-
nantly in elective PCI cases and were more frequent in lower mortality hospitals.
Bleeding complications occurred in 1,535 cases overall (0.39%) and modestly increased
from 0.27% in very low mortality hospitals to 0.57% in very high mortality hospitals (OR, 1.95;
95% CI, 1.58–2.39; Table 3A). Mortality in patients who developed bleeding complications is
summarized in Table 3B. Of the 1,535 patients with overall bleeding complications, 270
(17.6%) died during hospitalization. Unlike the trend for incidence of bleeding complications,
in-hospital mortality after bleeding complications increased markedly by quintile (Fig 2) and
was 6-fold higher in very high mortality hospitals compared to very low mortality hospitals
(29.0% vs. 4.8%; OR, 12.2; 95% CI, 6.90–21.7). Incidence of bleeding at the access site (0.21%)
and non-access sites (0.19%) was similar. Incidence of bleeding complications at non-access
sites tended to be higher in the higher mortality hospitals: the bleeding at non-access sites was
3 times higher in very high mortality hospitals than very low mortality hospitals (0.34% vs.
0.098%; OR, 3.17; 95% CI, 2.41–4.16). However, this tendency was weaker for access site bleed-
ing complications (0.24% vs. 0.18%; OR, 1.33; 95% CI, 1.03–1.71; Table 3A). In-hospital mor-
tality was twice as high after bleeding complications at non-access sites (25.4%) than after
bleeding complications at the access site (11.1%). Mortality after bleeding complications dif-
fered greatly between very high and very low mortality hospitals for both bleeding complica-
tions at non-access sites (35.2% vs. 6.7%; OR, 17.7; 95% CI, 8.07–38.8) and the access site
(20.9% vs. 3.7%; OR, 7.52; 95% CI, 3.29–17.2; Table 3B).
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Table 1. Patient characteristics.
Overall Very low mortality Low mortality Medium mortality High mortality Very high mortality P value
Number of PCI cases 388,866 106,591 73,323 69,096 71,206 68,650
In-hospital death 4,048 (1.04) 232 (0.22) 419 (0.57) 665 (0.96) 1,040 (1.46) 1,692 (2.46) <0.001
Age, years 71 ± 11 70 ± 11 71 ± 11 70 ± 11 71 ± 11 70 ± 11 <0.001
Male 297,464 (76) 81,702 (77) 56,083 (76) 53,224 (77) 54,043 (76) 52,412 (76) <0.001
Smoking within 1 year 119,873 (31) 36,263 (34) 20,373 (28) 20,000 (29) 23,310 (33) 19,927 (29) <0.001
Diabetes 173,147 (45) 47,151 (44) 32,592 (44) 29,787 (43) 32,723 (46) 30,894 (45) <0.001
Hypertension 291,399 (75) 79,640 (75) 54,403 (74) 51,973 (75) 54,306 (76) 51,077 (74) <0.001
Dyslipidemia 254,172 (65) 69,010 (65) 47,421 (65) 45,134 (65) 48,336 (68) 44,271 (64) <0.001
Chronic kidney disease 76,229 (20) 20,493 (19) 13,744 (19) 13,029 (19) 15,263 (21) 13,700 (20) <0.001
Maintenance dialysis 27,059 (7.0) 7,692 (7.2) 5,082 (6.9) 4,533 (6.6) 5,349 (7.5) 4,403 (6.4) <0.001
COPD 10,088 (2.6) 2,627 (2.5) 2,140 (2.9) 1,572 (2.3) 1,997 (2.8) 1,752 (2.6) <0.001
Peripheral vascular disease 30,292 (7.8) 7,784 (7.3) 5,710 (7.8) 5,406 (7.8) 5,824 (8.2) 5,568 (8.1) <0.001
Previous PCI 180,453 (46) 51,093 (48) 34,781 (47) 31,119 (45) 32,536 (46) 30,924 (45) <0.001
Previous CABG 14,148 (3.6) 3,570 (3.3) 2,709 (3.7) 2,552 (3.7) 2,970 (4.2) 2,347 (3.4) <0.001
Previous heart failure 57,042 (15) 14,883 (14) 11,486 (16) 9,731 (14) 11,132 (16) 9,810 (14) <0.001
Cardiogenic shock within 24 hours 13,419 (3.5) 3,568 (3.3) 2,710 (3.7) 2,481 (3.6) 2,513 (3.5) 2,147 (3.1) <0.001
Baseline hemoglobin, g/dL 13.2 ± 2.0 13.1 ± 2.0 13.2 ± 2.1 13.2 ± 2.0 13.2 ± 2.1 13.2 ± 2.1 0.002
Clinical presentation <0.001
Acute setting 148,715 (38) 37,878 (36) 27,998 (38) 27,591 (40) 28,476 (40) 26,772 (39)
STEMI 68,910 (18) 17,355 (16) 12,755 (17) 12,963 (19) 12,799 (18) 13,038 (19)
NSTEMI 21,217 (5.5) 5,285 (5.0) 3,779 (5.2) 4,163 (6.0) 4,047 (5.7) 3,943 (5.7)
UA 58,591 (15) 15,238 (14) 11,467 (16) 10,465 (15) 11,630 (16) 9,791 (14)
Access site <0.001
Transfemoral 98,625 (25) 29,931 (28) 20,493 (28) 17,816 (26) 15,694 (22) 14,691 (21)
Transradial 270,838 (70) 70,475 (66) 49,230 (67) 48,565 (70) 51,593 (72) 50,975 (74)
Number of diseased vessels
One 237,110 (61) 65,293 (61) 45,205 (62) 41,736 (60) 43,912 (62) 40,964 (60) <0.001
Two 92,749 (24) 25,375 (24) 17,089 (23) 16,868 (24) 16,409 (23) 17,008 (25) <0.001
Three 42,796 (11) 11,501 (11) 8,070 (11) 7,658 (11) 7,672 (11) 7,895 (12) <0.001
Left main 16,211 (4.2) 4,422 (4.1) 2,959 (4.0) 2,834 (4.1) 3,213 (4.5) 2,783 (4.1) <0.001
Target vessel
RCA 130,262 (33) 35,714 (34) 24,453 (33) 22,857 (33) 23,930 (34) 23,308 (34) 0.01
LMCA and/or LAD 204,398 (53) 55,981 (53) 37,876 (52) 35,790 (52) 38,159 (54) 36,592 (53) <0.001
LCX 95,475 (25) 26,517 (25) 18,043 (25) 15,989 (23) 17,849 (25) 17,077 (25) <0.001
Antithrombotic agents given at time of PCI
Antiplatelet agents 357,447 (92) 97,149 (91) 65,072 (89) 63,565 (92) 67,774 (95) 63,887 (93) <0.001
Aspirin 345,703 (89) 93,953 (88) 62,893 (86) 61,652 (89) 65,597 (92) 61,608 (90) <0.001
Clopidogrel 135,698 (35) 37,721 (35) 24,565 (34) 26,661 (39) 24,292 (34) 22,459 (33) <0.001
Prasugrel 191,263 (49) 50,054 (47) 35,993 (49) 31,079 (45) 37,380 (52) 36,757 (54) <0.001
Ticagrelor 468 (0.1) 219 (0.2) 94 (0.1) 68 (0.1) 53 (0.1) 34 (0.05) <0.001
Anticoagulant agents 26,309 (6.8) 6,694 (6.3) 4,950 (6.8) 4,962 (7.2) 5,129 (7.2) 4,574 (6.7) <0.001
Warfarin 10,378 (2.7) 2,793 (2.6) 1,972 (2.7) 1,805 (2.6) 2,014 (2.8) 1,794 (2.6) <0.001
Dabigatran 1,410 (0.4) 348 (0.3) 260 (0.4) 297 (0.4) 236 (0.3) 269 (0.4) 0.01
Rivaroxaban 5,004 (1.3) 1,326 (1.2) 834 (1.1) 907 (1.3) 1,026 (1.4) 911 (1.3) <0.001
Apixaban 5,388 (1.4) 1,260 (1.2) 1,078 (1.5) 1,110 (1.6) 1,037 (1.5) 903 (1.3) <0.001
Edoxaban 4,128 (1.1) 1,046 (1.0) 824 (1.1) 799 (1.2) 795 (1.1) 664 (1.0) 0.051
Dual antiplatelet therapy 316,061 (81) 84,998 (80) 58,456 (80) 55,841 (81) 59,763 (84) 57,003 (83) <0.001
(Continued)
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TFA was associated with an approximately 10-fold higher incidence of bleeding complica-
tions than TRA (0.61% vs. 0.065%). As shown in Fig 3A, TFA-related bleeding complications
tended to occur more frequently in higher mortality hospitals. Incidence of TFA-related bleed-
ing in very high and very low mortality hospitals was 0.76% and 0.44%, respectively. In con-
trast, incidence of TRA-related bleeding complications was relatively similar across quintiles.
Mortality after bleeding complications was identical in the TFA and TRA groups (12%). Con-
sistent with the main analysis results, mortality after TFA-related bleeding differed greatly
between very high and very low mortality hospitals (22.5% vs. 3.0%), but the trend was weaker
in the TRA-related bleeding group (20.5% vs. 7.1%; Fig 3B). Therefore, among TFA patients,
the incidence of bleeding complications and subsequent death increased by quintile. Incidence
of bleeding and subsequent death for very high and very low mortality hospitals was 0.17%
and 0.013%, respectively. This trend was also observed in TRA patients, but the absolute
Table 1. (Continued)
Overall Very low mortality Low mortality Medium mortality High mortality Very high mortality P value
Triple therapy� 19,205 (4.9) 4,623 (4.3) 3,727 (5.1) 3,550 (5.1) 3,951 (5.5) 3,354 (4.9) <0.001
Therapeutic devices
Balloon 335,129 (86) 95,165 (89) 61,721 (84) 60,228 (87) 57,895 (81) 60,120 (88) <0.001
BMS 3,169 (0.81) 764 (0.72) 657 (0.90) 527 (0.76) 817 (1.1) 404 (0.59) <0.001
DES 329,590 (85) 89,029 (84) 61,966 (85) 58,776 (85) 60,893 (86) 58,926 (86) <0.001
Rotational atherectomy 15,772 (4.1) 5,108 (4.8) 2,733 (3.7) 2,436 (3.5) 2,906 (4.1) 2,589 (3.8) <0.001
DCA 2,256 (0.58) 746 (0.70) 619 (0.84) 446 (0.65) 198 (0.28) 247 (0.36) <0.001
Values are expressed as means ± standard deviation or numbers (%). Chronic kidney disease was defined as the presence of proteinuria, and/or a serum creatinine level
�1.3 mg/dL, and/or an estimated glomerular filtration rate level�60 mL/min per 1.73 m2.
BMS, bare metal stent; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DCA, directional coronary atherectomy; DES, drug-
eluting stent; LAD, left anterior descending artery; LCX, left circumflex artery; LMCA, left main coronary artery; NSTEMI, non-ST-segment elevation myocardial
infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.
�Triple therapy indicates an anticoagulant agent plus dual antiplatelet therapy.
https://doi.org/10.1371/journal.pone.0261371.t001
Table 2. Institutional characteristics.
Overall Very low mortality Low mortality Medium mortality High mortality Very high mortality P value
Number of institutions 718 144 143 144 143 144
Number of PCI cases 452 (268–
702)
634 (461–875) 429 (294–650) 420 (244–630) 398 (204–610) 383 (210–672) <0.001
Number of institutions by PCI cases per
year
<0.001
<100 cases 116 (16) 1 (0.7) 17 (12) 28 (19) 35 (24) 35 (24)
100 to <500 cases 534 (74) 117 (81) 117 (81) 107 (74) 95 (66) 98 (68)
500 to <1000 cases 60 (8.4) 23 (16) 8 (5.6) 9 (6.3) 10 (6.9) 10 (6.9)
�1000 cases 8 (1.1) 3 (2.1) 1 (0.7) 0 (0.0) 3 (2.1) 1 (0.7)
In-hospital mortality, %
Expected mortality 1.0 (0.7–1.4) 1.1 (0.8–1.3) 1.1 (0.8–1.5) 1.0 (0.8–1.4) 1.0 (0.7–1.4) 0.9 (1.6–1.2) 0.004
Crude mortality 0.9 (0.4–1.7) 0.2 (0.2–0.3) 0.5 (0.4–0.8) 1.0 (0.7–1.2) 1.4 (1.0–2.0) 2.4 (1.6–3.3) <0.001
Risk-adjusted mortality 0.9 (0.5–1.7) 0.2 (0.2–0.3) 0.5 (0.5–0.6) 0.9 (0.8–1.0) 1.5 (1.3–1.7) 2.6 (2.2–3.4) <0.001
Values are expressed as medians (interquartile range) or numbers (%).
PCI, percutaneous coronary intervention.
https://doi.org/10.1371/journal.pone.0261371.t002
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number of events was extremely low. In these patients, incidence of bleeding and subsequent
death for very high and very low mortality hospitals was 0.016% and 0.0043%, respectively
(Fig 3C).
Table 3. Incidence of bleeding complications and in-hospital death in patients who developed bleeding complications.
Overall Very low mortality Low mortality Medium mortality High mortality Very high mortality P for trend
(A) Incidence of bleeding complications
Overall 1,535 (0.39) 291 (0.27) 245 (0.33) 322 (0.47) 284 (0.40) 393 (0.57) <0.001
Reference 1.25 (1.01–1.55) 1.72 (1.39–2.12) 1.57 (1.27–1.94) 1.95 (1.58–2.39)
Non-access site 744 (0.19) 104 (0.098) 98 (0.13) 160 (0.23) 149 (0.21) 233 (0.34) <0.001
Reference 1.36 (1.00–1.85) 2.34 (1.76–3.11) 2.25 (1.69–3.00) 3.17 (2.41–4.16)
Access site 829 (0.21) 190 (0.18) 161 (0.22) 170 (0.25) 145 (0.20) 163 (0.24) 0.02
Reference 1.28 (0.99–1.64) 1.40 (1.09–1.80) 1.21 (0.94–1.57) 1.33 (1.03–1.71)
(B) In-hospital death in patients who developed bleeding complications
Overall 270 (17.6) 14 (4.8) 30 (12.2) 52 (16.1) 60 (21.1) 114 (29.0) <0.001
Reference 3.10 (1.62–5.94) 5.63 (3.07–10.3) 6.64 (3.65–12.1) 12.2 (6.90–21.7)
Non-access site 189 (25.4) 7 (6.7) 24 (24.4) 35 (21.9) 41 (27.5) 82 (35.2) <0.001
Reference 4.96 (2.11–11.7) 7.61 (3.34–17.3) 9.06 (4.01–20.5) 17.7 (8.07–38.8)
Access site 92 (11.1) 7 (3.7) 10 (6.2) 19 (11.2) 22 (15.2) 34 (20.9) <0.001
Reference 2.07 (0.78–5.49) 4.15 (1.72–9.99) 4.76 (2.01–11.3) 7.52 (3.29–17.2)
The upper row of each line shows the number of events (%) and the lower row shows the odds ratio (OR) with 95% confidence interval (CI) in each quintile (calculated
relative to very low mortality hospitals).
https://doi.org/10.1371/journal.pone.0261371.t003
Fig 2. Incidence of overall bleeding complications and in-hospital mortality in patients who developed bleeding
complications. When divided hospitals into quintiles according to their risk-adjusted mortality, the bleeding
complication rate increased modestly from 0.27% to 0.57% in very low to very high mortality hospitals. However, the
mortality rate in patients who developed bleeding complications markedly increased from 4.8% to 29.0% in very low to
very high mortality hospitals.
https://doi.org/10.1371/journal.pone.0261371.g002
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Discussion
This study examined 388,866 PCI procedures performed at 718 hospitals and registered within
the J-PCI registry. Our main findings are as follows: (i) institutional variation in in-hospital
mortality after PCI was associated with procedure-related bleeding complications; (ii) this var-
iation was mainly caused by differences in mortality of patients who developed bleeding com-
plications rather than crude incidence of bleeding complications; (iii) this trend was
consistently observed in both bleeding complications from non-access and access site.
In-hospital mortality after PCI varies widely between hospitals [12–14]. Our results are in
agreement, as in-hospital mortality in this study ranged from 0.22% to 2.46% in very low to
very high mortality hospitals. Incidence of PCI-related bleeding events has also been reported
to vary widely across institutions [18]. However, we found only modest variation across the
studied hospitals. In contrast, mortality after bleeding complications varied significantly. Fail-
ure to rescue, defined as death in patients who develop a major procedural complication, is
well established as an indicator of surgical quality of care [19]. In addition, institutional differ-
ences in failure-to-rescue rates underlie the wide variation in in-hospital mortality after sur-
gery [20, 21]. The results obtained from our study were consistent with these reports, this
concept may be applied to PCI (i.e., institutional differences in failure-to-rescue rates after
bleeding complications underlie the wide variation in in-hospital mortality after PCI).
In this study, a tendency that variation in in-hospital mortality was mainly driven by differ-
ence in mortality after bleeding complications was consistently observed in both those from
access and non-access site. Moreover, among access site-related bleeding complications, TRA
Fig 3. Comparison between transfemoral and transradial access. Hospitals were stratified into quintiles according to risk-adjusted mortality. The blue and
green bars indicate the following rates for transfemoral access (TFA) and transradial access (TRA), respectively: (A) Incidence of bleeding complications. (B)
Mortality in patients who developed bleeding complications. (C) Incidence of bleeding complications and subsequent in-hospital death.
https://doi.org/10.1371/journal.pone.0261371.g003
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and TFA showed a similar trend. Previous studies revealed that TRA for PCI is associated with
lower risk of complications than TFA [3–5]. Similarly, our study showed a 10-fold lower inci-
dence of bleeding complications for TRA compared to TFA. However, given that higher mor-
tality hospitals had higher mortality rate after bleeding complications even in patients treated
via TRA, appropriate management after bleeding complications will be required regardless
method of access. Of note, higher mortality hospitals used TRA more frequently. In those hos-
pitals, TFA patients were more prone to develop bleeding complications as well as subsequent
in-hospital death. Similarly, in the Minimizing Adverse Haemorrhagic Events by TRansradial
Access Site and Systemic Implementation of angioX (MATRIX) trial, prognosis of TFA
patients was worse in institutions with higher use of TRA. The incidence of net ischemic and
bleeding events in TFA patients according to low, intermediate, and high use of TRA was
8.9%, 9.5%, and 17.1% [5]. The worse prognosis in institutions that more frequently use TRA
might be caused by increased incidence of TFA-related adverse events.
This study has several important limitations. First, the definition of bleeding complications
in the current study was different from standardized definitions, such as the definition from
Thrombolysis in Myocardial Infarction trial [22], the Global Use of Strategies to Open
Occluded Arteries trial [23], or the Bleeding Academic Research Consortium [24]. This may
have underestimated the actual incidence of bleeding complications in this study. Second, we
cannot determine the causality between bleeding complications and death during hospitaliza-
tion. However, failure to rescue, defined by all-cause death after major perioperative complica-
tions, is well established as an indicator of the surgical quality of care [19]. The results in our
study were equivalent to these reports, and this concept may be applied to PCI. Third, blood
transfusion practices and thresholds vary between hospitals [25], which may have affected our
results. Fourth, the number of variables in the J-PCI registry is limited and measured or
unmeasured confounders were present. Although we used a logistic regression model to
reduce potential confounding, we cannot completely eliminate this limitation. Finally, the
quality of the database used in this study is a significant issue. However, data in the J-PCI regis-
try are audited regularly to ensure accuracy.
In conclusion, institutional variation in in-hospital mortality after PCI was associated with
procedure-related bleeding complications, and this variation was largely driven by differences
in mortality after bleeding complications. These findings underscore the importance of efforts
toward reducing not only bleeding complications but also, even more importantly, subsequent
mortality once they have occurred. Further study is warranted on strategies for enabling
improvement of clinical outcomes after bleeding complications.
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